ArticleGynecologic oncology reports2022
Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study.
Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Impact of Allostatic Load on Overall Survival in Patients With Endometrial Cancer.Cancer medicine · 2026Article
- A Single-Cell Atlas of Uterine Carcinosarcoma from Diverse Ancestries.bioRxiv : the preprint server for biology · 2026Article
- Agreement between Surveillance, Epidemiology, and End Results- and Medicare Claims-Derived Uterine Cancer Treatment Data.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Epidemiological and Histopathological Characterization of Endometrial Carcinoma: A Retrospective Cohort from Romania.Diagnostics (Basel, Switzerland) · 2025Article
- FBXW7 Directly Ubiquitinates and Degrades CTNNB1 Mediating the Suppression of ENKUR in Endometrial Cancer.International journal of biological sciences · 2025Article
- Endometrial cancer survival in populations of African descent.American journal of epidemiology · 2024Article
- Single-nuclei sequencing of uterine serous carcinoma reveals racial differences in immune signaling.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Racial disparities in the treatment of endometrial intraepithelial neoplasia in postmenopausal women.Gynecologic oncology reports · 2024Article
- Lymphedema self-assessment among endometrial cancer survivors.Cancer causes & control : CCC · 2024Article
- Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.Gynecologic oncology · 2024Article
- Race- associated molecular differences in uterine serous carcinoma.Frontiers in oncology · 2024Article
- An Overview of Endometrial Cancer with Novel Therapeutic Strategies.Current oncology (Toronto, Ont.) · 2023Review
- Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer.JAMA network open · 2023Article
- Overall and progression-free survival in endometrial carcinoma: A single-center retrospective study of patients treated between 2000-2018.Annals of Saudi medicineArticle
- Cancer treatment and survivorship statistics, 2025.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine overall survival (OS) and cancer-specific survival (CSS) for different racial groups of women with surgically staged endometrial cancer by histologic subtype.
methodsThis is a retrospective cohort study of women with stage I-III endometrioid, serous, clear cell, and carcinosarcoma who underwent hysterectomy as primary surgical staging in the 2000-2016 SEER-Medicare database. OS and CSS outcomes were stratified by race (defined as White, Black, Other), stage, and histology. Survival was assessed with descriptive analyses, log-rank tests and unadjusted and adjusted multivariable cox regression models.
resultsOf the 24,142 women identified, 85.5% were White, 8.5% Black, and 6% other races. Receipt of adjuvant therapy differed only for stage III endometrioid: Black women were less likely to receive adjuvant treatment after hysterectomy (61.2% vs. 70.1% White, p = 0.03). For stage I, Black women had worse CSS for all histologies other than clear cell in unadjusted and adjusted analyses. For stage II, Black women had worse CSS for endometrioid histology in unadjusted analyses and similar OS. For stage III, Black women with endometrioid carcinoma had worse CSS and OS in unadjusted analyses, but no significant difference in CSS in adjusted analyses. "Other" race showed improved OS for Stage I endometrioid adenocarcinoma without significant differences in outcomes when compared to White women.
conclusionAcross histologies other than clear cell, Black women diagnosed with stage I endometrial cancer had consistently worse CSS, despite similar receipt of adjuvant therapy. Differences in CSS and OS at higher stages disappeared once accounting for treatment disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.